Showing 4421-4430 of 5646 results for "".
- CooperVision Announces Uniform Markings Across Blanchard Onefit Family of Scleral Lenseshttps://modernod.com/news/coopervision-announces-uniform-markings-across-blanchard-onefit-family-of-scleral-lenses/2479312/CooperVision Specialty EyeCare announced that lens markings are now uniform across the entire Blanchard Onefit family of scleral lenses, including Onefit MED and Onefit MED+. The uniform markings for front torics and toric haptics across the Onefit family aid in distinguishing whether quadrant sp
- Oyster Point Announces Enrollment of First Subject in the OLYMPIA Phase 2 Clinical Trial for Patients with Neurotrophic Keratopathyhttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-the-olympia-phase-2-clinical-trial-for-patients-with-neurotrophic-keratopathy/2479308/Oyster Point Pharma announced enrollment of the first subject in the OLYMPIA phase 2 clinical trial of OC-01 (varenicline) nasal spray for the treatment of Stage 1 Neurotrophic Keratopathy (NK). “This is an exciting milestone as we continue to develop this potentially new tr
- Implandata’s Receives CE Mark for the EYEMATE-SC Biosensor for Remote Glaucoma Carehttps://modernod.com/news/implandatas-receives-ce-mark-for-the-eyemate-sc-biosensor-for-remote-glaucoma-care/2479310/Implandata Ophthalmic Products announced that its EYEMATE-SC biosensor has obtained CE Mark. This device is used in conjunction with the EYEMATE system for digitally enabled remote glaucoma monitoring and management. The patented EYEMATE system is the world’s only clinically-validated pro
- Zubisoft Launches New IOL Treatment Plannerhttps://modernod.com/news/zubisoft-launches-new-iol-treatment-planner/2479307/Switzerland-based Zubisoft and IBRA have released a new IOL treatment planner, which is now a part of IBRA Cataract Services. In addition to higher visual acuity, the new planner allows surgeons to achieve more accurate results. The lower rate of necessary retreatments results in cost savings for
- US Looks to Spur Advances in COVID-19 Antivirals With $3.2-Billion Infusionhttps://modernod.com/news/us-looks-to-spur-advances-in-covid-19-antivirals-with-3-2-billion-infusion/2479304/The US Department of Health and Human Services (HHS) said Thursday that it is allocating $3.2 billion toward the discovery, development and manufacturing of antivirals as part of its strategy to support the next-generation of COVID-19 treatments, according to a FirstWord report. “New antivi
- Alcon’s ORA System Reaches 2 Million Caseshttps://modernod.com/news/alcons-ora-system-reaches-2-million-cases/2479303/Alcon announced its Optiwave Refractive Analysis (ORA) intraoperative aberrometer system has reached 2 million cases worldwide. This milestone signifies an important leap forward in cataract surgery by delivering greater accuracy than preoperative calculation methods alone. The ORA Syste
- Scientists Unravel the Function of a Sight-Saving Growth Factorhttps://modernod.com/news/scientists-unravel-the-function-of-a-sight-saving-growth-ffactor/2479302/Researchers at the National Eye Institute (NEI) have determined how certain short protein fragments, called peptides, can protect neuronal cells found in the light-sensing retina layer at the back of the eye. The peptides might someday be used to treat degenerative retinal diseases, such as age-r
- The Vision Council Releases Results of the 2020 Internet Influence Reporthttps://modernod.com/news/the-vision-council-releasese280afresults-of-the-2020-internet-influence-report/2479298/The Vision Council has released the results of the “Internet Influence Report.” Conducted in December 2020, the special interest consumer report examines the role of the Internet among consumers who recently purchased different types of eyewear. The Vision Council fielded
- Arnaud Lacoste Is Named Chief Scientific Officer of Aurion Biotechhttps://modernod.com/news/arnaud-lacoste-is-named-chief-scientific-officer-of-aurion-biotech/2479293/Arnaud Lacoste, MBA, PhD, has been named chief scientific officer of Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies. Arnaud will lead R&D teams based in Boston and Seattle. “Arnaud is a brilliant scientist, a strategic e
- Visus Therapeutics Announces Executive Leadership Appointments in Operations, Research, Clinical Operations and Intellectual Propertyhttps://modernod.com/news/visus-therapeutics-announces-executive-leadership-appointments-in-operations-research-clinical-operations-and-intellectual-property/2479290/Visus Therapeutics announced the appointment of six new senior leaders, including Tim Grinstead as Chief Operating Officer; James Burke as Vice President of Research; Patrick Hughes, PhD, as Vice President of Pharmaceutical Development; Lisa Simpson as Vice President of Clinical Operations and Co